ASPE SCHEDULE 13G: SEC filing
Frazier Life Sciences X, L.P. and affiliated reporting persons
Filed with the SEC on · accession 0001231919-26-001553
ASPE filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 9, 2026. Frazier Life Sciences X, L.P. and affiliated reporting persons filed a Schedule 13G disclosing beneficial ownership of 1,674,321 shares, or 5.8%, of Aspen Neuroscience's common stock following the company's IPO.
Summary of the filing
Frazier Life Sciences X, L.P. and affiliated reporting persons filed a Schedule 13G disclosing beneficial ownership of 1,674,321 shares, or 5.8%, of Aspen Neuroscience's common stock following the company's IPO. The filing is a passive investment disclosure with no intent to influence control.
Key details
✦ Ask GOAX AI about this filing — what it means for ASPE, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ASPE?
Click hereFrequently asked questions
What did ASPE file with the SEC on Nov 9, 2026?
ASPE filed a SCHEDULE 13G (SEC filing). Frazier Life Sciences X, L.P. and affiliated reporting persons filed a Schedule 13G disclosing beneficial ownership of 1,674,321 shares, or 5.8%, of Aspen Neuroscience's common stock following the company's IPO. The filing is a passive investment disclosure with no intent to influence control.
How do I read a SCHEDULE 13G?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).
Other ASPE SEC filings
Get alerts when ASPE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days